Rocket Pharmaceuticals (RCKT) Leases: 2018-2025
Historic Leases for Rocket Pharmaceuticals (RCKT) over the last 7 years, with Sep 2025 value amounting to $40.7 million.
- Rocket Pharmaceuticals' Leases fell 5.02% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year decrease of 5.02%. This contributed to the annual value of $42.4 million for FY2024, which is 4.84% down from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Leases is $40.7 million, which was down 1.30% from $41.3 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Leases ranged from a high of $50.3 million in Q1 2021 and a low of $200,000 during Q1 2023.
- Moreover, its 3-year median value for Leases was $42.9 million (2024), whereas its average is $39.3 million.
- As far as peak fluctuations go, Rocket Pharmaceuticals' Leases crashed by 99.58% in 2023, and later spiked by 21,889.50% in 2024.
- Over the past 5 years, Rocket Pharmaceuticals' Leases (Quarterly) stood at $48.5 million in 2021, then decreased by 3.75% to $46.7 million in 2022, then decreased by 4.60% to $44.5 million in 2023, then decreased by 4.84% to $42.4 million in 2024, then dropped by 5.02% to $40.7 million in 2025.
- Its last three reported values are $40.7 million in Q3 2025, $41.3 million for Q2 2025, and $41.8 million during Q1 2025.